UniProt P29323 · PDB · AlphaFold · Substrate: pEY + Mn · Clone: aa 616-889high-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Ponatinib | 100.0% | 0.0% | 78.23 | 0.534 |
| 2 | Bosutinib | 99.8% | 0.2% | 87.22 | 0.555 |
| 3 | Nilotinib | 98.7% | 1.3% | 96.49 | 0.765 |
| 4 | Tivozanib | 98.0% | 2.0% | 92.42 | 0.673 |
| 5 | Dasatinib | 97.9% | 2.1% | 87.97 | 0.699 |
| 6 | Cabozantinib | 94.5% | 5.5% | 92.73 | 0.751 |
| 7 | Repotrectinib | 93.5% | 6.5% | 84.21 | 0.608 |
| 8 | Ripretinib | 91.5% | 8.5% | 92.95 | 0.674 |
| 9 | Vandetanib | 70.9% | 29.1% | 95.74 | 0.723 |
| 10 | Erdafitinib | 69.0% | 31.0% | 95.71 | 0.737 |
| 11 | Alectinib | 64.2% | 35.8% | 95.49 | 0.651 |
| 12 | Nintedanib | 59.6% | 40.4% | 90.23 | 0.608 |
| 13 | Selpercatinib | 59.2% | 40.8% | 96.72 | 0.635 |
| 14 | Crizotinib | 57.4% | 42.6% | 91.39 | 0.581 |
| 15 | Afatinib | 57.1% | 42.9% | 98.50 | 0.709 |
| 16 | Canertinib | 54.3% | 45.7% | 96.49 | 0.671 |
| 17 | Gilteritinib | 45.9% | 54.1% | 88.97 | 0.506 |
| 18 | Fostamatinib | 42.1% | 57.9% | 96.74 | 0.613 |
| 19 | Apatinib | 42.1% | 57.9% | 97.73 | 0.704 |
| 20 | Pacritinib | 41.8% | 58.2% | 88.64 | 0.452 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 3.64
- Epithelial log2(TPM+1): 2.50
- Fold change: 1.15
- Status: Upregulated
High-confidence drugs
- Nilotinib — inh 98.7% · KISS 49.93
- Tivozanib — inh 98.0% · KISS 40.96
- Dasatinib — inh 97.9% · KISS 39.96
Selectivity landscape vs inhibition on EPHB2
Each point is one of the 92 approved drugs; color = inhibition % on EPHB2.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…